Atlantis Health co-authored a poster presented at the International Myeloma Society Annual Meeting in Athens and at Blood 2023, the Annual Scientific Meeting of the Haematology Society of Australia and New Zealand. We described a co-designed patient support program delivered by Atlantis Health that offered personalized, multichannel support to patients at key time points aligned with their XPO-1 inhibitor treatment for relapsed/refractory multiple myeloma.

Designed in collaboration with Antengene (AUS) Pty Ltd, Myeloma Australia and healthcare professionals, the program complements the care provided by their hospital-based treating team in achieving optimal patient outcomes. 

“Patient support programs can have a significant impact on healthcare outcomes and the overall patient experience. Pleased to see how this additional layer of support provided by Myeloma Australia nurses to multiple myeloma patients via the X-TEND program has helped patients with their healthcare literacy, empowering them to take an active role in their health.” - Nirmal Lorensuhewa, Medical Science Liaison, Antengene (AUS) 

"I proudly acknowledge and celebrate the collaborative efforts of Antengene, Atlantis and Myeloma Australia in shaping the X-TEND patient support program for people with relapsed myeloma commencing on XPO-1 inhibitor treatment. Together we have advanced care and support for those at a critical timepoint in their treatment trajectory." - Emma-Jane Furphy, Senior Myeloma Nurse and Special Projects, Myeloma Australia.